Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691179 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL774435 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2198163 | 0.90 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2075658 | 0.89 | KDM4E (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15313206 | 0.85 | USP2 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15299228 | 0.81 | BRD4 (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL710775 | 0.81 | BRD4 (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL5315549 | 0.81 | BRD4 (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2199583 | 0.80 | KDM4E (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2197047 | 0.79 | KDM4E (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735430-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735430-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20130030022-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130030022-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-8299103-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299103-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| US-7037916-B2 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2004062609-A2 | PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063192-A1 | IMIDAZOLYL PYRIMIDINE DERIVATIVES USEFUL AS IL-8 RECEPTOR MODULATORS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA, LLC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | KDM4E 3304/4885USP2 4003/4885ALDH1A1 2313/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | KDM4E 3304/4885USP2 4003/4885ALDH1A1 2313/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | KDM4E 4586/4885USP2 4168/4885ALDH1A1 1673/4885 |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | CXCL8, IL1RN, IL18 | KDM4E 4646/4885USP2 3999/4885ALDH1A1 1217/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | KDM4E 3304/4885USP2 4003/4885ALDH1A1 2313/4885 |
| US-20130030022-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KDM4E 3300/4885USP2 4243/4885ALDH1A1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.